Loading...
•
Mar 31, 2022
Agenus Q1 2022 Earnings Report
Agenus reported first quarter 2022 financial results and provided a corporate update.
Key Takeaways
Agenus reported a revenue of $26 million for the quarter ended March 31, 2022, an increase of $14 million compared to the same quarter in 2021. The net loss for the quarter was $51 million, with per share losses of $0.19. The company ended the quarter with $263 million in cash and short-term investments.
Prioritizing most promising clinical programs, including botensilimab combinations.
AGEN1571 clinical trials to commence; preclinical data presented at AACR.
Milestone payment received from Gilead for the clinical advancement of AGEN2373 targeting CD137.
Initiated cost containment measures with expected reductions in operating expenses in coming quarters.
Forward Guidance
Agenus has initiated cost containment measures with expected reductions in operating expenses in coming quarters.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...